Logo Medical Data Models (MDM) Portal Logo Westfälische Wilhelms-Universität (WWU)
Information:
Error:
en ▾
  • Deutsch
  • English
  • Español
  • Italiano
  • Français
  • Português
  • Svenska
  • Nederlands
  • Login
  • Register
  • Search
  • ODM-XML file upload
  • Create data model
  • ODM-Edit tool
  • Metadata Registry
  • Help
  • About the MDM portal
  • Imprint
  • Login
  • Register
Actions ▾
  • ODM-XML file upload
  • Create data model
  • ODM-Edit tool
  • Metadata Registry
  • About the MDM portal
en ▾
  • Deutsch
  • English
  • Español
  • Italiano
  • Français
  • Português
  • Svenska
  • Nederlands

Search through specific fields of a model

The name of the data model contains study:
name:"study"
The description contains two terms:
description:"double blind"
The copyrightholder contains the term UKM:
copyrightholder:"UKM"
The uploader of the model is Martin Dugas:
uploader:"Martin Dugas"
The keywords contain cancer:
keyword:"cancer"

Refine the search with search operators

Search for groups of words with quotes:
"leukemia myeloid"
Use a wildcard to search for prefixes:
NCT*
With AND/OR/NOT find study without eye nor ear:
study AND NOT (eye OR ear)
Cancer must (+) occur, study not (-):
+cancer -study
You may connect the different search techniques:
name:"form*" AND routine
  • Filter search results
Keywords
Diagnostic Techniques, Neurological ×
  • Clinical Trial  (8)
  • Multiple Sclerosis  (8)
  • Multiple Sclerosis, Relapsing-Remitting  (7)
  • Evoked Potentials  (7)
  • Artificial Intelligence  (1)
  • Biological Markers  (1)
  • Cell Phones  (1)
  • Mobile Applications  (1)
  • Medical History Taking  (1)
  • Movement Disorders  (1)
  • Parkinson Disease  (1)
Show more Keywords
Table of contents
  1. 1. Clinical Trial
  2. 2. Routine Documentation
  3. 3. Registry/Cohort Study
  4. 4. Quality Assurance
  5. 5. Data Standard
  6. 6. Patient-Reported Outcome
  7. 7. Medical Specialty
  • Select data models
Selected data models

You must log in to select data models for download or further analysis.

9 Search results.

Sort (Relevance) ▾
  • Relevance
  • Rating
  • New first
  • Old first

Smart Device System Meta Data Definitions - PD NMS

- 9/3/20 - 7 forms, 1 itemgroup, 1 item, 2 languages
Itemgroup: PD NMS
Metadata definitions for the Smart Device System for Movement Disorders. Clinical Protocol and Registration Information available on: https://clinicaltrials.gov/ct2/show/NCT03638479 Principal Investigator: Julian Varghese Description for Assessment Steps for Neurologic Examination are available under: Varghese J, Niewöhner S, Soto-Rey I, et al. A Smart Device System to Identify New Phenotypical Characteristics in Movement Disorders. Front Neurol. 2019;10:48. doi:10.3389/fneur.2019.00048
  • Mobile Applications
  • Cell Phones
  • Movement Disorders
  • Parkinson Disease
  • Diagnostic Techniques, Neurological
  • Artificial Intelligence
  • Biological Markers
  • Medical History Taking

Neurologic Examination

1 itemgroup, 6 items

Demography

2 itemgroups, 5 items

Medical History

1 itemgroup, 9 items

Family History

1 itemgroup, 2 items
2 other form meeting the search is available in the detailed view.

Baseline Visit (Day 1): EDSS evaluation BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS) (ENDORSE) NCT00835770

- 6/9/16 - 1 form, 4 itemgroups, 15 items, 1 language
Itemgroups: Subject Identification, EDSS Evaluation, Functional System Scores, EDSS, Additional and Results
The primary objective of this study is to evaluate the long-term safety profile of BG00012 (dimethyl fumarate). Secondary objectives of this study are to evaluate the long-term efficacy of BG00012 using clinical endpoints and disability progression, to evaluate further the long-term effects of BG00012 on multiple sclerosis (MS) brain lesions on magnetic resonance imaging (MRI) scans in participants who had MRI scans as part of Studies 109MS301 (NCT00420212) and 109MS302 (NCT00451451) and to evaluate the long-term effects of BG00012 on health economics assessments and the visual function test. NCT00835770 Part: Baseline Visit (Day 1)
  • Diagnostic Techniques, Neurological
  • Multiple Sclerosis
  • Clinical Trial

Baseline: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378 - Baseline: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 33 items, 1 language
Itemgroup: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Baseline
  • Evoked Potentials
  • Multiple Sclerosis
  • Clinical Trial
  • Multiple Sclerosis, Relapsing-Remitting
  • Diagnostic Techniques, Neurological

Month 6: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 33 items, 1 language
Itemgroup: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 6
  • Evoked Potentials
  • Multiple Sclerosis, Relapsing-Remitting
  • Multiple Sclerosis
  • Diagnostic Techniques, Neurological
  • Clinical Trial

Month 12: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 33 items, 1 language
Itemgroup: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 12
  • Diagnostic Techniques, Neurological
  • Multiple Sclerosis
  • Clinical Trial
  • Multiple Sclerosis, Relapsing-Remitting
  • Evoked Potentials

Month 30: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 33 items, 1 language
Itemgroup: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 30
  • Diagnostic Techniques, Neurological
  • Clinical Trial
  • Evoked Potentials
  • Multiple Sclerosis, Relapsing-Remitting
  • Multiple Sclerosis

Month 24: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 33 items, 1 language
Itemgroup: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 24
  • Diagnostic Techniques, Neurological
  • Multiple Sclerosis, Relapsing-Remitting
  • Evoked Potentials
  • Multiple Sclerosis
  • Clinical Trial

Month 36: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 33 items, 1 language
Itemgroup: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 36
  • Diagnostic Techniques, Neurological
  • Evoked Potentials
  • Multiple Sclerosis
  • Clinical Trial
  • Multiple Sclerosis, Relapsing-Remitting

Month 18: Evoked Potentials Multiple Sclerosis ALAIN01 NCT02419378

- 6/3/16 - 1 form, 1 itemgroup, 33 items, 1 language
Itemgroup: Evoked Potentials
Alemtuzumab in Autoimmune Inflammatory Neurodegeneration: Mechanisms of Action and Neuroprotective Potential (ALAIN01) https://clinicaltrials.gov/ct2/show/NCT02419378 Principal Investigator Prof. Dr. Dr. Sven Meuth, University Hospital Muenster, Germany Part: Month 18
  • Diagnostic Techniques, Neurological
  • Multiple Sclerosis
  • Evoked Potentials
  • Clinical Trial
  • Multiple Sclerosis, Relapsing-Remitting
  • 1

Contact

Institute of Medical Informatics
Director: Prof. Dr. Martin Dugas
Albert-Schweitzer-Campus 1, A11
48149 Münster, Germany
Email : imi@uni-muenster.de

In collaboration with

Logo DFG Logo ERCIS Logo IMI Logo CatRIS Logo ULB Logo IH-D Logo Toolpool Logo EFMI
  • Imprint
  • Disclaimer
  • Data Privacy
© 2021  University of Münster
  • Contact
  • Help
  • Cite

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Login

Forgot password?


Register